![Flavia Borellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 4 M $ in data 31/05/2026
Flavia Borellini currently serves as Independent Director at Cantargia AB since 2020, Independent Director at Revolution Medicines, Inc. since 2021, Director at Kartos Therapeutics, Inc. since 2018, and as a Member of Roche Group.
Former roles include Chief Executive Officer at Acerta Pharma BV from 2016 to 2019, Independent Director at Viracta Therapeutics, Inc. from 2021 to 2025, VP-Global Product & Portfolio Strategy at AstraZeneca PLC from 2018 to 2020, and Vice President-Program Leadership at Onyx Pharmaceuticals, Inc. from 2012 to 2013.
Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 18/06/2026 | 26.215 ( 0,01% ) | 4 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Direttore/Membro del Consiglio | 22/06/2021 |
| CANTARGIA AB | Direttore/Membro del Consiglio | 01/10/2020 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Direttore/Membro del Consiglio | 01/02/2018 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
| Società | Posizione | Fine |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 05/02/2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Amministratore Delegato | 01/02/2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/10/2013 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
